Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
Trial details
- Registry ID
- NCT02612311
- Phase
- Phase 3
The FDA approved Obinutuzumab (GAZYVA) on 1 Nov 2013.
Drug identity checked against registry records
Also recorded as GAZYVA
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaNCT02612311 | TGTX | Phase 3 | Terminated | 2023-02-22Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2013-11-01Day | Obinutuzumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125486", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["GAZYVA"], "active_ingredients": ["OBINUTUZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20131101", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |